Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

Open access

Abstract

High Resolution Image Download MS PowerPoint Slide Hyperactivation of mTOR kinase by mutations in the PI3K/mTOR pathway or by crosstalk with other mutant cancer drivers, such as RAS, is a feature of many tumors. Multiple allosteric inhibitors of mTORC1 and orthosteric dual inhibitors of mTORC1 and mTORC2 have been developed as anticancer drugs, but their clinical utility has been limited. To address these limitations, we have developed a novel class of “bi-steric inhibitors” that interact with both the orthosteric and the allosteric binding sites in order to deepen the inhibition of mTORC1 while also preserving selectivity for mTORC1 over mTORC2. In this report, we describe the discovery and preclinical profile of the development candidate RMC-5552 and the in vivo preclinical tool compound RMC-6272. We also present evidence that selective inhibition of mTORC1 in combination with covalent inhibition of KRAS G12C shows increased antitumor activity in a preclinical model of KRAS G12C mutant NSCLC that exhibits resistance to KRAS G12C inhibitor monotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.2c01658

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Rapamycin, FK-506, Rapalink-1, and representative mTOR inhibitors.
Figure 1 Rapamycin, FK-506, Rapalink-1, and representative mTOR inhibitors.CC BY · PubMed Central
Scheme 1 Synthesis of C40-Ether Triazole-Linked Bi-Steric Inhibitors Reagents and conditions: (i) hex-5-yn-1-yl trifluoromethanesulfonate, 2,6-di-tert-butyl-4-methylpyridine, DCM, from 0 °C to rt, 30% yield; (ii) RN3, Cu(MeCN)4PF6, TBTA, DMSO, rt, 20–62% yield; (iii) RN3, CuSO4, sodium ascorbate, MeOH, rt, 18–37% yield.
Scheme 1 Synthesis of C40-Ether Triazole-Linked Bi-Steric Inhibitors Reagents and conditions: (i) hex-5-yn-1-yl trifluoromethanesulfonate, 2,6-di-tert-butyl-4-methylpyridine, DCM, from 0 °C to rt, 30% yield; (ii) RN3, Cu(MeCN)4PF6, TBTA, DMSO, rt, 20–62% yield; (iii) RN3, CuSO4, sodium ascorbate, MeOH, rt, 18–37% yield.CC BY · PubMed Central
Scheme 2 Synthesis of C40-Carbamate-Linked Bi-Steric Inhibitors Reagents and conditions: (i) R = C=O (rapamycin); p-nitrophenyl chloroformate, py, DCM, −78 °C, 59% yield. (ii) R = (R)-CH(OH); p-nitrophenyl chloroformate, py, 4 Å molecular sieves, DCM, from −15 °C to −10 °C, 63% yield or R = (R)–CH(OMe), from −10 °C to rt, 85% yield. (iii) R1NH2, DIPEA, DMA, rt, 36–63% yield.
Scheme 2 Synthesis of C40-Carbamate-Linked Bi-Steric Inhibitors Reagents and conditions: (i) R = C=O (rapamycin); p-nitrophenyl chloroformate, py, DCM, −78 °C, 59% yield. (ii) R = (R)-CH(OH); p-nitrophenyl chloroformate, py, 4 Å molecular sieves, DCM, from −15 °C to −10 °C, 63% yield or R = (R)–CH(OMe), from −10 °C to rt, 85% yield. (iii) R1NH2, DIPEA, DMA, rt, 36–63% yield.CC BY · PubMed Central
Scheme 3 Synthesis of Ring-Opened Seco-Analogs, and Structure of Secorapamycin Reagents and conditions: (i) NH4OAc, DMA, 40 °C, 28% yield.
Scheme 3 Synthesis of Ring-Opened Seco-Analogs, and Structure of Secorapamycin Reagents and conditions: (i) NH4OAc, DMA, 40 °C, 28% yield.CC BY · PubMed Central
Figure 2 Structural representation of binding sites for FKBP12-rapamycin and active-site inhibitors in mTORC1 and mTORC2. Rapamycin has reduced affinity for mTORC2 due to partial occlusion of the FKBP12-rapamycin binding (FRB) domain, while active-site inhibitors have similar affinity for both complexes. Reprinted by permission from Springer Nature ref (58). Copyright 2021.
Figure 2 Structural representation of binding sites for FKBP12-rapamycin and active-site inhibitors in mTORC1 and mTORC2. Rapamycin has reduced affinity for mTORC2 due to partial occlusion of the FKBP12-rapamycin binding (FRB) domain, while active-site inhibitors have similar affinity for both complexes. Reprinted by permission from Springer Nature ref (58). Copyright 2021.CC BY · PubMed Central
Figure 3 Bi-steric inhibitor 16 undergoes ring opening of the rapamycin macrocycle in vivo to form ring-opened 32. (A) Mouse PK: male Balb/c mice (n = 3), IP = 3 mg/kg. (B) Rat PK: male Sprague–Dawley rats (n = 3), IV bolus = 1 mg/kg; vehicle = transcutol/solutol HS15/H2O 5%/5%/90% (v,w,v).
Figure 3 Bi-steric inhibitor 16 undergoes ring opening of the rapamycin macrocycle in vivo to form ring-opened 32. (A) Mouse PK: male Balb/c mice (n = 3), IP = 3 mg/kg. (B) Rat PK: male Sprague–Dawley rats (n = 3), IV bolus = 1 mg/kg; vehicle = transcutol/solutol HS15/H2O 5%/5%/90% (v,w,v).CC BY · PubMed Central
Figure 4 Rapamycin analogs 11 (PDB 8ER6) and 12 (PDB 8ER7) bind at FKBP12’s canonical rapamycin binding site. (A) Hydroxy analog 11 (darker orange) binds in the FKBP12 (red) pocket partially defined by residue F47. C32 hydroxyl residue donates an intramolecular hydrogen bond with the adjacent ester oxygen (dashed line). (B) Methyl ether 12 (lighter orange) is not able to form this intramolecular hydrogen bond, and the methyl group is oriented toward FKBP12 residue F47. As a result, F47 must shift upward to accommodate this additional steric bulk.
Figure 4 Rapamycin analogs 11 (PDB 8ER6) and 12 (PDB 8ER7) bind at FKBP12’s canonical rapamycin binding site. (A) Hydroxy analog 11 (darker orange) binds in the FKBP12 (red) pocket partially defined by residue F47. C32 hydroxyl residue donates an intramolecular hydrogen bond with the adjacent ester oxygen (dashed line). (B) Methyl ether 12 (lighter orange) is not able to form this intramolecular hydrogen bond, and the methyl group is oriented toward FKBP12 residue F47. As a result, F47 must shift upward to accommodate this additional steric bulk.CC BY · PubMed Central
Figure 5 (A) Local resolution map of the mTORC1-RMC-5552-FKBP12 cryo-EM structure (PDB 8ERA). Higher resolution core of the map allows for confident modeling of side chains and both the rapalog-like and the ATP-competitive moieties of RMC-5552. N-HEAT domain of mTOR (right) and WD40 domain of Raptor (left) are more disordered than other regions of the map and consequently approach 7 Å. (B) Cryo-EM map of mTORC1-FKBP12-RMC-5552 38 complex. mTORC1-FKBP12-RMC-5552 38 complex cryo-EM map is shown colored by protomer. Blue is mTOR, green is Raptor, purple is mLST8, and red is FKBP12. (C) Cryo-EM map reveals density for rapalog moiety of RMC-5552 38 binding at its expected location between FKBP12 and the FRB domain at threshold 0.0033. (D) Cryo-EM map reveals density corresponding to the ATP-competitive moiety of RMC-5552 38 (orange) binding mTOR (blue) at its orthosteric site at threshold 0.024. Multiple hydrogen bonds are formed between mTOR and ligand, including with mTOR residues K2187, E2190, G2238, and V2240 (black dashed lines). 4-Aminopyrazolo[3,4-d]pyrimidine core of RMC-5552 π stacks with the aromatic side chain of mTOR residue W2239 (purple dashed line). Density (gray transparent surface) does not extend beyond the beginning of the linker region.
Figure 5 (A) Local resolution map of the mTORC1-RMC-5552-FKBP12 cryo-EM structure (PDB 8ERA). Higher resolution core of the map allows for confident modeling of side chains and both the rapalog-like and the ATP-competitive moieties of RMC-5552. N-HEAT domain of mTOR (right) and WD40 domain of Raptor (left) are more disordered than other regions of the map and consequently approach 7 Å. (B) Cryo-EM map of mTORC1-FKBP12-RMC-5552 38 complex. mTORC1-FKBP12-RMC-5552 38 complex cryo-EM map is shown colored by protomer. Blue is mTOR, green is Raptor, purple is mLST8, and red is FKBP12. (C) Cryo-EM map reveals density for rapalog moiety of RMC-5552 38 binding at its expected location between FKBP12 and the FRB domain at threshold 0.0033. (D) Cryo-EM map reveals density corresponding to the ATP-competitive moiety of RMC-5552 38 (orange) binding mTOR (blue) at its orthosteric site at threshold 0.024. Multiple hydrogen bonds are formed between mTOR and ligand, including with mTOR residues K2187, E2190, G2238, and V2240 (black dashed lines). 4-Aminopyrazolo[3,4-d]pyrimidine core of RMC-5552 π stacks with the aromatic side chain of mTOR residue W2239 (purple dashed line). Density (gray transparent surface) does not extend beyond the beginning of the linker region.CC BY · PubMed Central
Figure 6 Tumor PD after a single dose of each inhibitor in the MCF-7 CDX model: (A) RMC-5552 38 and RMC-6272 40; (B) sapanisertib 5 and everolimus 4.
Figure 6 Tumor PD after a single dose of each inhibitor in the MCF-7 CDX model: (A) RMC-5552 38 and RMC-6272 40; (B) sapanisertib 5 and everolimus 4.CC BY · PubMed Central
Figure 7 Mean tumor volume over time in MCF-7 CDX model for (A) RMC-5552 38 and (B) RMC-6272 40. Data were analyzed by two-way repeated measures ANOVA; ** p < 0.01 and *** p < 0.001, as compared to control at end of study. Mean percentage body weight change for (C) RMC-5552 38 and (D) RMC-6272 40.
Figure 7 Mean tumor volume over time in MCF-7 CDX model for (A) RMC-5552 38 and (B) RMC-6272 40. Data were analyzed by two-way repeated measures ANOVA; ** p < 0.01 and *** p < 0.001, as compared to control at end of study. Mean percentage body weight change for (C) RMC-5552 38 and (D) RMC-6272 40.CC BY · PubMed Central
Figure 8 (A) Mean tumor volume over time, (B) mean percentage body weight change, and (C) caspase-3 cleavage staining 24 h post a single dose for RMC-6272 40, sotorasib, and the combination in the NCI-H2122 CDX model.
Figure 8 (A) Mean tumor volume over time, (B) mean percentage body weight change, and (C) caspase-3 cleavage staining 24 h post a single dose for RMC-6272 40, sotorasib, and the combination in the NCI-H2122 CDX model.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Research works printed but not linked: 23

  1. Sehgal, S. N.; Blazekovic, T. M.; Vezina, C. Rapamycin und seine herstellung. Patent application number DE1973-2347682, 1973; Chem Abstr. 1974 , 81 , 24166.
  2. Sehgal, S. N.; Blazekovic, T. M.; Vézina, C. Rapamycin and process of preparation. U.S. Patent 3,929,992, 1975; Chem Abstr. 1976 , 85 , 3861.
  3. Sehgal, S. N.; Blazekovic, T. M.; Vezina, C. Rapamycin and process of preparation. U.S. Patent 3,993,749, 1976; Chem Abstr. 1977 , 86 , 41806.
  4. Sidorowicz, H.; Baker, H.; Vézina, C. Rapamycin (AY-22,989), a new antifungal antibiotic: in vitro and in vivo studies. 15th Interscience Conference on Antimicrobial Agents and Chemotherapy , Sept 24–26, 1975, Washington, DC; American Society for Microbiology, 1975; Abstract 26.
  5. Morris R. E., 1989, Med. Sci. Res., 17, 609
  6. aSehgal, S. N.; Vézina, C. Compositions pharmaceutiques à base de rapamycine pour le traitement de tumeurs carcinogens. Patent number BE877700, 1980; Chem Abstr. 1980 , 93 , 88940. See also.
  7. Eng, C. P. Combination of rapamycin and picibanil for the treatment of tumors. U.S. Patent 4,401,653, 1983; Chem Abstr. 1983 , 98 , 22284.
  8. Shokat, K.; Okaniwa, M. mTORCl inhibitors. WO2016040806, 2016; Chem Abstr. 2016 , 164 , 412316.
  9. Ren, P.; Liu, Y.; Li, L.; Chan, K.; Wilson, T. E. Benzoxazole kinase inhibitors and methods of use. WO2010051043, 2010; Chem Abstr. 2010 , 152 , 542024.
  10. Semko, C.; Pitzen, J.; Wang, G.; Tibrewal, N.; Aggen, J. B.; Thottumkara, A. P.; Burnett, G. L.; Gliedt, M. J. E.; Kiss, G.; Won, W.; Lee, J. C.; Gill, A. L. Rapamycin analogs as mTOR inhibitors. WO2018204416, 2018; Chem Abstr. 2018 , 169 , 525729.
  11. Pitzen, J.; Gliedt, M. J. E.; Burnett, G. L.; Aggen, J. B.; Kiss, G.; Cregg, J. J.; Semko, C. M.; Won, W.; Wang, G.; Lee, J. C-L.; Thottumkara, A. P.; Gill, A. L.; Mellem, K. T. C40- C28- and C32-linked rapamycin analogs as mTOR inhibitors. WO2019212990, 2019; Chem Abstr. 2019 , 171 , 558403.
  12. Semko, C. M.; Wang, G.; Burnett, G. L.; Aggen, J. B.; Kiss, G.; Cregg, J. J.; Gliedt, M. J. E.; Pitzen, J.; Lee, J. C-L.; Won, W.; Thottumkara, A. P.; Gill, A. L. C26-linked rapamycin analogs as mTOR inhibitors. WO2019212991, 2019; Chem Abstr. 2019 , 171 , 551179.
  13. Mahauad-Fernandez, W. D.; Yang, Y. C.; Lai, I.; Park, J.; Yao, L.; Evans, J. W.; Burnett, L. G.; Gill, A.; Smith, J. A. M.; Singh, M.; Felsher, D. W. Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapy; https://www.biorxiv.org/content/10.1101/2022.02.04.478208v1. · doi:10.1101/2022.02.04.478208v1
  14. Tibrewal N., 2018, Proceedings of the AACR Special Conference on Targeting PI3K/mTOR Signaling
  15. Yang Y. C., 2020, Proceedings of the Annual Meeting of the American Association for Cancer Research 2020, Virtual Meeting II
  16. Burnett G. L., 2021, Proceedings of the Annual Meeting of the American Association for Cancer Research 2021, Virtual Meeting I
  17. Mahauad-Fernandez W., 2021, Proceedings of the Annual Meeting of the American Association for Cancer Research 2021, Virtual Meeting I
  18. Du H., 2021, Proceedings of the Annual Meeting of the American Association for Cancer Research 2021, Virtual Meeting I
  19. Cottens, S.; Sedrani, R. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants. WO9409010, 1994; Chem Abstr. 1994 , 122 , 9774.
  20. Hu, D. C. Preparation of rapamycin carbonate esters as immunosuppressant agents. U.S. Patent 5,260,300, 1993; Chem Abstr. 1993 , 120 , 269937.
  21. Nelson, F. C. 27-hydroxyrapamycin and derivatives thereof. U.S. Patent 5,256790, 1993; Chem Abstr. 1993 , 121 , 9034.
  22. Cottens, S.; Sedrani, R. Synthesis and immunosuppressant activity of rapamycin derivatives. WO9641807, 1996; Chem Abstr. 1996 , 126 , 157342.
  23. Zhu, T. Oxepane isomer of 42-O-(2-hydroxyethyl)rapamycin. U.S. Patent 7,241,771, 2007; Chem Abstr. 2006 , 145 , 292763.

Cited by

See all 73

Metadata

Authors
Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., Tomlinson, A. C. A., Kiss, G., Tzitzilonis, C., Thottumkara, A. P., Cregg, J., Mellem, K. T., Choi, J. S., Lee, J. C., Zhao, Y., Lee, B. J., Meyerowitz, J. G., Knox, J. E., Jiang, J., Wang, Z., Wildes, D., Wang, Z., Singh, M., Smith, J. A. M., & Gill, A. L.
Affiliations
Revolution Medicines (United States) (US)
Corresponding author
  • Burnett, G. Leslie
  • Gill, Adrian L.
Venue
Journal of Medicinal Chemistry
Published
2022-12-19
Volume
66
Issue
1
Pages
149-169
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4311927080
Cited by
72
References
74
Citations by year
2026: 25 · 2025: 19 · 2024: 11 · 2023: 17
FWCI
3.92
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
mTORC1 inhibition, PI3K/mTOR pathway, KRAS G12C, non-small cell lung cancer, anticancer drug discovery
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Mechanistic Target of Rapamycin Complex 2, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors. https://app.cochat.ai/papers/10.1021/acs.jmedchem.2c01658
The paper
Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., Tomlinson, A. C. A., Kiss, G., Tzitzilonis, C., Thottumkara, A. P., Cregg, J., Mellem, K. T., Choi, J. S., Lee, J. C., Zhao, Y., . . . Gill, A. L. (2023). Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01658

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.